University of Huddersfield, UK.
International Medical University, Kuala Lumpur, Malaysia.
J Atten Disord. 2022 Feb;26(3):467-475. doi: 10.1177/1087054721997556. Epub 2021 Mar 5.
We investigated the prescription trends and adverse drug reactions (ADRs) of ADHD drugs in primary care, England between 2010 and 2019.
The Prescription Cost Analysis database presenting the primary care prescriptions data and the Interactive Drug Analysis Profiles presenting all suspected ADRs reported for each drug were screened. The data were analyzed using linear regression analysis to examine the annual average change per year.
The prescription items dispensed for ADHD showed an average 11.07% (95% CI 10.54-11.60, = .001) increase per year and there was a mean 11.54% (95% CI 11.03-12.06, = .001) increase per year in the costs. The overall reporting of serious and fatal ADR was reduced by 1.79% per year for ADHD drugs. Guanfacine showed a 40% mean increase per year.
The increasing use of ADHD drugs within primary care in England could be a result of multiple factors such as growing ADHD prevalence.
我们调查了 2010 年至 2019 年期间英国初级保健中注意力缺陷多动障碍（ADHD）药物的处方趋势和药物不良反应（ADR）。
筛选了呈现初级保健处方数据的处方成本分析数据库和呈现每种药物报告的所有疑似 ADR 的交互式药物分析档案。使用线性回归分析来检查每年的平均变化率来分析数据。
ADHD 的配药处方项目每年平均增长 11.07%（95%CI 10.54-11.60，=0.001），费用每年平均增长 11.54%（95%CI 11.03-12.06，=0.001）。ADHD 药物的严重和致命 ADR 总体报告每年减少 1.79%。胍法辛每年平均增长 40%。
英国初级保健中 ADHD 药物的使用不断增加可能是 ADHD 患病率上升等多种因素造成的。
